Moleculin Biotech (MBRX) Competitors $2.45 -0.15 (-5.77%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MBRX vs. ITRM, PLUR, LSTA, ESLA, BTAI, BIVI, BGXX, IBIO, GLYC, and RNXTShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Iterum Therapeutics (ITRM), Pluri (PLUR), Lisata Therapeutics (LSTA), Estrella Immunopharma (ESLA), BioXcel Therapeutics (BTAI), BioVie (BIVI), Bright Green (BGXX), iBio (IBIO), GlycoMimetics (GLYC), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Iterum Therapeutics Pluri Lisata Therapeutics Estrella Immunopharma BioXcel Therapeutics BioVie Bright Green iBio GlycoMimetics RenovoRx Iterum Therapeutics (NASDAQ:ITRM) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has more risk and volatility, ITRM or MBRX? Iterum Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Which has stronger valuation and earnings, ITRM or MBRX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$38.37M-$2.00-0.61Moleculin BiotechN/AN/A-$29.77MN/AN/A Does the MarketBeat Community favor ITRM or MBRX? Moleculin Biotech received 86 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. However, 62.95% of users gave Iterum Therapeutics an outperform vote while only 51.01% of users gave Moleculin Biotech an outperform vote. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Moleculin BiotechOutperform Votes22751.01% Underperform Votes21848.99% Do insiders and institutionals hold more shares of ITRM or MBRX? 9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 9.2% of Iterum Therapeutics shares are owned by insiders. Comparatively, 7.1% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate ITRM or MBRX? Iterum Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 309.84%. Moleculin Biotech has a consensus price target of $35.00, suggesting a potential upside of 1,328.57%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Iterum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ITRM or MBRX more profitable? Iterum Therapeutics' return on equity of 0.00% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -113.59% Moleculin Biotech N/A -105.50%-79.03% Does the media prefer ITRM or MBRX? In the previous week, Iterum Therapeutics had 2 more articles in the media than Moleculin Biotech. MarketBeat recorded 4 mentions for Iterum Therapeutics and 2 mentions for Moleculin Biotech. Iterum Therapeutics' average media sentiment score of 0.46 beat Moleculin Biotech's score of 0.41 indicating that Iterum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iterum Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIterum Therapeutics and Moleculin Biotech tied by winning 6 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.97M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93114.8115.14Price / SalesN/A396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book0.215.324.665.02Net Income-$29.77M$153.56M$119.06M$225.46M7 Day Performance-4.85%0.13%0.80%0.37%1 Month Performance-2.78%15.23%5.65%3.57%1 Year Performance-67.99%41.14%36.75%29.43% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech1.9509 of 5 stars$2.45-5.8%$35.00+1,328.6%-66.1%$6.97MN/A0.0020ITRMIterum Therapeutics2.8355 of 5 stars$1.22-5.4%$5.00+309.8%+67.1%$27.71MN/A-0.6110Gap UpHigh Trading VolumePLURPluri0.7863 of 5 stars$4.85-3.2%N/A+14.4%$26.53M$330,000.00-0.82150Gap DownLSTALisata Therapeutics2.9284 of 5 stars$3.16+11.7%$15.00+374.7%+51.2%$26.29MN/A-1.2330Upcoming EarningsAnalyst RevisionNews CoverageHigh Trading VolumeESLAEstrella Immunopharma1.3098 of 5 stars$0.73-8.8%N/A-52.5%$26.27MN/A-0.37N/APositive NewsGap DownBTAIBioXcel Therapeutics4.1811 of 5 stars$0.64-3.0%$5.00+677.5%-85.4%$26.20M$1.38M-0.1890Short Interest ↑News CoverageBIVIBioVie2.5741 of 5 stars$2.77+1.1%$4.00+44.4%-39.8%$25.84MN/A-0.2010Gap DownBGXXBright GreenN/A$0.13-5.4%N/A-63.5%$24.85MN/A-2.172Gap DownIBIOiBio1.0468 of 5 stars$2.70+4.2%$4.30+59.3%N/A$24.68M$220,000.000.00100GLYCGlycoMimetics4.3862 of 5 stars$0.38-5.0%$10.00+2,513.7%-69.6%$24.67M$10,000.00-0.6650Analyst ForecastOptions VolumeNews CoverageRNXTRenovoRx2.3436 of 5 stars$1.02+2.2%$6.13+500.5%-3.8%$24.47MN/A-1.706Positive News Related Companies and Tools Related Companies ITRM Competitors PLUR Competitors LSTA Competitors ESLA Competitors BTAI Competitors BIVI Competitors BGXX Competitors IBIO Competitors GLYC Competitors RNXT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MBRX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
